Edition:
United States

Neuralstem Inc (CUR.OQ)

CUR.OQ on NASDAQ Stock Exchange Capital Market

1.66USD
20 Apr 2018
Change (% chg)

$-0.05 (-2.92%)
Prev Close
$1.71
Open
$1.72
Day's High
$1.72
Day's Low
$1.65
Volume
6,130
Avg. Vol
51,351
52-wk High
$6.58
52-wk Low
$0.89

Chart for

About

Neuralstem, Inc. (Neuralstem) is a clinical-stage biopharmaceutical company. The Company is engaged in research, development and commercialization of central nervous system therapies based on its human neuronal stem cells and its stem-cell derived small molecule compounds. The Company has approximately three assets: its NSI-189... (more)
No analyst recommendations are available for .

Overall

Beta: 1.47
Market Cap(Mil.): $25.17
Shares Outstanding(Mil.): 15.16
Dividend: --
Yield (%): --

Financials

  CUR.OQ Industry Sector
P/E (TTM): -- 31.01 33.60
EPS (TTM): -1.30 -- --
ROI: -113.35 13.60 13.19
ROE: -158.04 15.26 15.00

BRIEF-Neuralstem Announces First Surgery Completed In Cervical Cohort Of Phase 1 Clinical Trial In Patients With Chronic Spinal Cord Injury

* NEURALSTEM ANNOUNCES FIRST SURGERY COMPLETED IN CERVICAL COHORT OF PHASE 1 CLINICAL TRIAL IN PATIENTS WITH CHRONIC SPINAL CORD INJURY Source text for Eikon: Further company coverage:

Apr 10 2018

BRIEF-Neuralstem Says At Dec. 31, 2017, Cash And Investments Was $11.7 Mln Compared To $20.2 Mln At Dec. 31, 2016

* NEURALSTEM REPORTS YEAR END 2017 FISCAL RESULTS AND BUSINESS UPDATE

Apr 02 2018

BRIEF-Neuralstem Q3 loss per share $0.01

* Neuralstem reports third quarter 2017 fiscal results and provides clinical and business update

Nov 13 2017

Earnings vs. Estimates